The estimated Net Worth of Kristiina Md Vuori is at least $169 mil dollars as of 29 August 2024. Kristiina Vuori owns over 7,140 units of Bionano Genomics Inc stock worth over $3,427 and over the last 8 years he sold BNGO stock worth over $165,497. In addition, he makes $0 as Independent Director at Bionano Genomics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kristiina Vuori BNGO stock SEC Form 4 insiders trading
Kristiina has made over 3 trades of the Bionano Genomics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 7,140 units of BNGO stock worth $99,960 on 29 August 2024.
The largest trade he's ever made was buying 7,140 units of Bionano Genomics Inc stock on 29 August 2024 worth over $99,960. On average, Kristiina trades about 513 units every 141 days since 2016. As of 29 August 2024 he still owns at least 7,140 units of Bionano Genomics Inc stock.
You can see the complete history of Kristiina Vuori stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kristiina Vuori biography
Dr. Kristiina Vuori M.D. Ph.D. serves as Independent Director of the Company. Dr. Vuori has served as President of Sanford Burnham Prebys Medical Discovery Institute, or the Institute, a non-profit research organization with major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. In addition, Dr. Vuori has also held the Pauline and Stanley Foster Presidential Chair at the Institute since January 2010 and served as the Institute’s interim Chief Executive Officer from January 2013 to September 2014, and from September 2017 to present. Since January 1995, Dr. Vuori has served as a Professor at the Institute’s National Cancer Institute designated Cancer Center, an interdisciplinary basic and translational research effort mobilizing over 400 scientists. In addition, from July 2014 to September 2017, Dr. Vuori served on the board of directors of WebMD, and she serves or has served in the past five years on the boards of directors of the American Association for Cancer Research, the California Institute for Regenerative Medicine, and the California Breast Cancer Research Council. Dr. Vuori earned her M.D. and Ph.D. from the University of Oulu, Finland. Our board of directors believes that Dr. Vuori’s experience in biomedical research and as an educator of research scientists, her experience managing a large non-profit research organization, and her various leadership roles qualify her to serve on our board of directors.
How old is Kristiina Vuori?
Kristiina Vuori is 52, he's been the Independent Director of Bionano Genomics Inc since 2019. There are 3 older and 3 younger executives at Bionano Genomics Inc. The oldest executive at Bionano Genomics Inc is David Barker, 78, who is the Independent Chairman of the Board.
What's Kristiina Vuori's mailing address?
Kristiina's mailing address filed with the SEC is C/O INHIBRX BIOSCIENCES, INC., 11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037.
Insiders trading at Bionano Genomics Inc
Over the last 6 years, insiders at Bionano Genomics Inc have traded over $0 worth of Bionano Genomics Inc stock and bought 145,814 units worth $129,149 . The most active insiders traders include David L Barker, Christopher P. Stewart, eChristopher J Twomey. On average, Bionano Genomics Inc executives and independent directors trade stock every 75 days with the average trade being worth of $15,253. The most recent stock trade was executed by Hannah Mamuszka on 13 June 2023, trading 65,789 units of BNGO stock currently worth $50,000.
What does Bionano Genomics Inc do?
at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o
What does Bionano Genomics Inc's logo look like?
Complete history of Kristiina Vuori stock trades at Bionano Genomics Inc, Axovant Gene Therapies, eInhibrx
Bionano Genomics Inc executives and stock owners
Bionano Genomics Inc executives and other stock owners filed with the SEC include:
-
R. Erik Holmlin,
President, Chief Executive Officer, Director -
Mark Oldakowski,
Chief Operating Officer -
Dr. Robert Erik Holmlin,
Pres, CEO, Sec. & Director -
David Barker,
Independent Chairman of the Board -
Christopher P. Stewart,
Chief Financial Officer -
Kristiina Vuori,
Independent Director -
Christopher Twomey,
Independent Director -
Albert Luderer,
Independent Director -
Hannah Mamuszka,
Director -
Yvonne Linney,
Director -
Alka Chaubey,
Chief Medical Officer -
Christopher Stewart,
Chief Financial Officer -
Dr. Charles Lee Ph.D.,
Scientific Advisor -
Prof. Pui-Yan Kwok,
Scientific Advisor -
Dr. Paul R. Selvin Ph.D.,
Scientific Advisor -
Mark Adamchak,
Controller -
Richard Shippy,
Chief Bus. Officer -
Robert J. Priar,
Chief Commercial Officer -
Dr. Alka Chaubey FACMG, Ph.D.,
Chief Medical Officer -
Aleksandar Rajkovic,
Director -
Robert J Priar,
Chief Commercial Officer -
Michael James Ward,
Former Chief Financial Officer -
Heather Adams,
Chief Administrative Officer -
Warren Robinson,
Chief Commercial Officer -
Darren Cai,
Director -
Quan Zhou,
Director -
Junfeng Wang,
Director -
Soheil Shams,
Chief Informatics Officer -
Richard Shippy,
Chief Business Officer -
Vincent Jung Fai Wong,
Director -
Jonathan V. Dixon,
GENERAL COUNSEL -
Gulsen Kama,
Chief Financial Officer